Dr. Erba on Second-Generation TKIs for Chronic Phase CML

Video

Harry Erba, MD, PhD, from the University of Alabama at Birmingham, discusses the use of second-generation tyrosine kinase inhibitors for the treatment of chronic phase chronic myeloid leukemia.

Harry Erba, MD, PhD, Professor of Medicine, Director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses the use of second-generation tyrosine kinase inhibitors (TKIs) for the treatment of chronic phase chronic myeloid leukemia (CML).

In chronic phase CML, Erba says, the goal is to prevent progression to accelerated phase and blast crisis, as it is associated with inferior survival. In clinical trials, nilotinib and dasatinib showed fewer progressions in the first two to three years compared to imatinib. Furthermore, Erba adds, the 2013 NCCN Guidelines dictate that at 3 months, patients with CML are expected to have a molecular response equivalent to a 1-log reduction in the BCR-ABL:ABL ratio. In general, in several trials, the second-generation TKIs showed a higher likelihood of achieving the 1-log milestone, demonstrating a physician's decreased chance of needing to change drugs early on.

In terms of side effects, Erba notes, the safety profiles are different in second-generation TKIs compared to imatinib but these side effects are manageable when treating patients for prolonged periods of time.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD